Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA

Table 2 Comparison of serum CA19-9 and CEA levels in patients with cholangiocarcinoma and benign biliary diseases

	CA19-9△	CA19-9	CEA	CA19-9 or CEA	CA19-9 and CEA
Sensitivity(true positive)*	65.71%(23/35)	77.14%(27/35)a	68.57%(24/35)	91.43%(32/35)	62.86%(22/35)
Specificity(true negative)**	88.04%(81/92)	84.78%(78/92)	81.52%(75/92)	76.09%(70/92)	86.96%(80/92)
Positive predictive value	67.65%(23/34)	65.85%(27/41)	58.54%(24/41)	59.26%(32/54)	64.71%(22/34)
Negative predictive value	87.10%(81/93)	90.70%(78/86)	87.21%(75/86)	95.89%(70/73)	88.89%(80/90)
Accuracy	81.89%(104/127)	82.68%(105/127)	77.95%(99/127)	80.31%(102/127)	80.31%(102/127)
False positive rate	11.98%(11/92)	15.22%(14/92)	18.48%(17/92)	23.91%(22/92)	13.04%(12/92)

*Number of positive tests/number of patients with cholangiocarcinoma. **Number of negative tests/number of patients with benign biliary diseases.

^aP < 0.05 vs CEA. ^△When the cutoff value of serum CA19-9 was 100 KU·L^-1